Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice.
This project aimed to explore the attitudes of prenatal genetic counselors toward discussion of novel approved and experimental CF treatments in the prenatal setting, and to assess how knowledge of genotype-specific, targeted treatments may influence their current practices. Targeted treatments have the potential to impact the health-related quality of life of individuals affected with CF and therefore, knowledge of the availability of such treatments may influence the decision-making process of parents who receive a fetal diagnosis of CF. Using the 2012 FDA approval and introduction of ivacaftor into CF clinical practice as a case study, a survey was designed to explore the opinions and practices of prenatal genetic counselors with regard to counseling for a prenatal diagnosis of CF, and how those practices might be impacted by the availability of a new genotype-specific treatment. Approximately 800 genetic counselors were sent questionnaires in January of 2013. Respondents were provided information about this treatment and were asked to rate its perceived benefits, along with the likelihood that they would discuss potential benefits and limitations with parents receiving a prenatal diagnosis of CF. One-hundred sixty-nine prenatal genetic counselors (21.1 %) responded to the survey. Results indicated that 80 % of respondents 'never heard of the drug', or they were 'not exactly sure' what it was. After reading the materials provided, counselors felt the new treatment would have 'some' or a 'significant' impact on an affected individual's life. Their opinions varied on what information about this treatment they would choose to discuss with their patients; even if the treatment is currently FDA approved and clinically available for affected individuals with the genotype of the fetus. However, they would 'definitely' refer these patients to a specialist to discuss targeted treatments further. Most prenatal genetic counselors indicated there are certain scenarios in the prenatal setting which warrant a discussion of targeted treatments for CF, at least on some level. Counselor's views on sharing information about new treatment options are shaped by their familiarity with the treatment and their perception of its benefits and limitations, their comfort discussing these subjects, and their interpretation of the genetic counselor's role. Most genetic counselors had never heard of ivacaftor or Kalydeco™ prior to taking the survey. Therefore, counselors need to be better educated about the availability of CFTR mutation-based treatments before they will be able to incorporate discussion of new treatment options into their counseling.
Sarah Lawrence College, Bronxville, NY, USA. crung@gm.slc.edu.
Caroline Rung
CR
Elsas
Mount Sinai Beth Israel, New York, NY, USA.
Elinor Langfelder
EL
Schwind
Sarah Lawrence College, Bronxville, NY, USA.
Laura
L
Hercher
Sarah Lawrence College, Bronxville, NY, USA.
Michael J
MJ
Smith
Mount Sinai Beth Israel, New York, NY, USA.
Kara Gardner
KG
Young
D000627:Aminophenols / Q000627:therapeutic use*; D001294:Attitude to Health; D065101:Chloride Channel Agonists / Q000627:therapeutic use; D000072117:Counselors; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics; D003657:Decision Making; D005260:Female; D005817:Genetic Counseling; D005820:Genetic Testing; D006801:Humans; D009154:Mutation; D010290:Parents / Q000523:psychology*; D057285:Precision Medicine; D011247:Pregnancy; D011296:Prenatal Diagnosis; D011788:Quality of Life; D015363:Quinolones / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D035703:Therapies, Investigational
D000627:Aminophenols; D065101:Chloride Channel Agonists; D015363:Quinolones; C545203:ivacaftor
Cystic fibrosis; Ivacaftor; Personalized medicine; Prenatal genetic counseling; Targeted treatments